Natriuretic Peptides in Heart Failure: From Diagnostic Blood Tests to Potential Treatments
This review examines how natriuretic peptides — especially ANP, BNP, and CNP — protect the heart, serve as key biomarkers for diagnosing heart failure, and hold promise as therapeutic agents.
Quick Facts
What This Study Found
The review consolidates evidence that natriuretic peptides serve a dual role in heart failure — as diagnostic biomarkers and as cardioprotective agents. ANP and BNP directly oppose the effects of angiotensin II through diuretic/natriuretic actions (promoting water and sodium excretion), vasodilation (relaxing blood vessels), and inhibition of aldosterone secretion. CNP primarily regulates vascular tone and blood pressure.
BNP and NT-proBNP (a cleavage product of proBNP processing) are elevated in heart failure patients and have become standard clinical biomarkers for detecting cardiac load. The review discusses how understanding the full biology of these peptides — from gene expression to receptor signaling — is informing development of natriuretic peptide-based therapeutics.
Key Numbers
Covers ANP, BNP, NT-proBNP, CNP as biomarkers and therapeutics; antagonistic to angiotensin II/aldosterone
How They Did This
This is a comprehensive narrative review synthesizing basic science research, clinical studies, and translational findings on the natriuretic peptide family. It covers the physiological functions of ANP, BNP, and CNP, their roles in cardiovascular homeostasis, pathophysiological changes in heart failure, and clinical applications as biomarkers and therapeutic agents.
Why This Research Matters
Heart failure affects tens of millions of people worldwide and remains a leading cause of hospitalization and death. Natriuretic peptide blood tests (BNP and NT-proBNP) have transformed how doctors diagnose and monitor heart failure, and understanding the underlying biology is critical for developing next-generation treatments. This review bridges the gap between basic peptide science and clinical cardiology.
The Bigger Picture
Natriuretic peptides are among the most clinically important peptide families in medicine. Their role extends beyond heart failure — they're implicated in hypertension, kidney disease, and metabolic syndrome. The therapeutic arm of this field includes sacubitril/valsartan (Entresto), which works by inhibiting the breakdown of natriuretic peptides, and ongoing research into direct ANP/BNP-based treatments. This review provides the foundational knowledge for understanding these developments.
What This Study Doesn't Tell Us
This is a narrative review and does not include new experimental data. It reflects one author's synthesis and interpretation of the literature. As a 2021 publication, it may not capture the most recent clinical trial data on natriuretic peptide-based therapeutics.
Questions This Raises
- ?Can direct natriuretic peptide-based therapies improve heart failure outcomes beyond what neprilysin inhibitors like sacubitril already achieve?
- ?How can natriuretic peptide testing be optimized to distinguish between different types and stages of heart failure?
- ?Could CNP-targeted therapies address vascular aspects of heart failure that ANP/BNP-based approaches miss?
Trust & Context
- Key Stat:
- BNP/NT-proBNP: standard heart failure biomarkers These natriuretic peptide measurements have become essential diagnostic tools, reflecting cardiac load and guiding treatment decisions in heart failure patients
- Evidence Grade:
- This is a narrative review article published in Pharmacology & Therapeutics, synthesizing decades of basic and clinical research. It provides an authoritative overview but does not present original data or systematic evidence grading.
- Study Age:
- Published in 2021, this review captures the state of natriuretic peptide research through 2020–2021, including the era of neprilysin inhibitor therapy (sacubitril/valsartan) and modern biomarker-guided treatment approaches.
- Original Title:
- The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications.
- Published In:
- Pharmacology & therapeutics, 227, 107863 (2021)
- Authors:
- Kuwahara, Koichiro(4)
- Database ID:
- RPEP-05520
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is a BNP blood test and why do doctors order it?
BNP (brain natriuretic peptide) and NT-proBNP are blood tests that measure levels of a heart-produced peptide. When the heart is stressed or enlarged, it releases more BNP. Elevated levels help doctors diagnose heart failure, assess its severity, and monitor how well treatments are working. It's one of the most important tests in cardiology.
Are natriuretic peptides used as actual treatments, not just tests?
Yes, in some ways. Carperitide (synthetic ANP) is used intravenously for acute heart failure in Japan. More widely, the drug sacubitril/valsartan (Entresto) works by preventing the breakdown of natriuretic peptides, effectively boosting their protective effects. Research continues into direct natriuretic peptide therapies.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05520APA
Kuwahara, Koichiro. (2021). The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications.. Pharmacology & therapeutics, 227, 107863. https://doi.org/10.1016/j.pharmthera.2021.107863
MLA
Kuwahara, Koichiro. "The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications.." Pharmacology & therapeutics, 2021. https://doi.org/10.1016/j.pharmthera.2021.107863
RethinkPeptides
RethinkPeptides Research Database. "The natriuretic peptide system in heart failure: Diagnostic ..." RPEP-05520. Retrieved from https://rethinkpeptides.com/research/kuwahara-2021-the-natriuretic-peptide-system
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.